Caitlin John’s ImmunityBio IBRX Stock Holding History

Caitlin John’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-500	Closed	-$3.83K	–	1027
2026 Q1	$3.83K	Hold	500	–	–	﹤0.01%	650
2025 Q4	$990	Sell	500 -500	-50%	-$1.13K	﹤0.01%	801
2025 Q3	$2.46K	Buy	+1,000	New	+$2.58K	﹤0.01%	666

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Caitlin John's IBRX Position: Q2 2026 in Review

Caitlin John sold out of ImmunityBio (IBRX) in Q2 2026, closing a stake of 500 shares — an estimated $3.83K sold.

Caitlin John first reported a position in IBRX in Q3 2025 and held it in 3 quarters. The position peaked at $3.83K in Q1 2026. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

Caitlin John reported no remaining ImmunityBio position as of Q2 2026 after selling out during the quarter.
Caitlin John sold 500 ImmunityBio shares in Q2 2026, an estimated $3.83K.
Caitlin John first reported a position in ImmunityBio in Q3 2025 and held it in 3 quarters.
Caitlin John's ImmunityBio position peaked at $3.83K in Q1 2026.
405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Caitlin John's 13F filing for Q2 2026, filed 17 Aug 2026.